Home
/
Sales of Therapeutic Antibodies and Proteins in 2022 close to US$ 300 bln with Antibodies contributing more than 80%
Posted In Blog

Sales of Therapeutic Antibodies and Proteins in 2022 close to US$ 300 bln with Antibodies contributing more than 80%

BARCELONA, Spain I March 08, 2023 I La Merie Publishing released the 17th edition of its report series about sales of recombinant biologics. The report 2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics provides a compilation of the sales data of originator and biosimilar recombinant therapeutic proteins and antibodies in the calendar year 2022. In addition, information about sales of novel biologics, i.e. gene & cell therapy and RNA, is presented.

Global sales of branded originator biologics increased by 7.3 % to US$ 291 bln compared with the previous year. Antibody sales represented 83.7% of total biologics sales in 2022. The strong growth of antibody sales was mainly driven by novel anti-inflammatory antibodies and immuno-oncology antibodies. Blockbuster status with 2022 sales exceeding US$ 1 bln was achieved by 71 recombinant biologic therapeutics. The sales data of 21 innovative antibodies and proteins were reported for the first time and include Aidexi; Anniko; Cejemly; Daxxify; Elahere; Enjaymo; Enweida; Hansizhuang; Idefirix; Inmazeb; Kimmtrak; Lunsumio; Opdualag; Rolvedon; Saphnelo; Skytrofa; Susvimo; Telitacicept; Tezspire; Vabysmo; Vyvgart; Xenpozyme.

The number of commercialized antibody-drug conjugates (ADC) is growing: the eleven reported ADCs achieved 2022 sales of US$ 7.4 bln. The report also provides sales information on T-cell recruiting bispecific antibodies and other bispecific antibodies.

Sales and growth rates of cancer antibodies were analyzed by subgroup, especially for the strongly growing class of PD-1 & PD-L1 antibodies of which information on 2022 sales of fifteen products could be identified.

While total sales of anti-TNF antibodies started to shrink (-3.4%), novel anti-inflammatory antibodies grew in 2022 by US$ 10.5 bln vs the previous year. The novel anti-inflammatory antibodies cover the therapeutic areas of dermatology, rheumatoid & autoimmune, neuroinflammation (multiple sclerosis and myasthenia gravis), pulmonary & respiratory and gastrointestinal.

Methodology

Sales data were obtained from company publications and refer to innovative branded products as well as biosimilars and other biologics (gene & cell therapy, antisense, siRNA). All sales data were converted from their original, reported currency into US$ using official currency exchange rates as of February 01, 2023. Sales figures represent the sum of revenues in all territories where the products are marketed. Growth rates mostly are presented as reported (in some cases on constant exchange rates).

What you will find in the report:

Biologics Sales per Class of Branded Originator Products

  • Sales of Established Therapeutic Proteins 2012 – 2022
  • Sales and Growth Rates of Cancer Antibodies by Subgroup 2012 – 2022
  • Sales and Growth Rates of Other Anti-Inflammatory Antibodies by Therapeutic Area 2012 – 2022
  • Sales of Antibody-Drug Conjugates by Product 2012 – 2022
  • Published Biosimilar Sales 2022 by Company
  • Published 2022 Sales of Other Biologics Based on DNA, RNA & Cells

TOP 30 Company Ranking List for Sales of Innovator Biologics 2022

Blockbuster Biologics in 2022 (by generic name)

Biologic Product Sales 2022:

  1. Cancer Antibodies

1.1 PD-1 & PD-L1 Immuno-Oncology Antibodies

1.2 Other Immuno-Oncology Antibodies

1.3. Cancer Antibodies:

1.3.1 Her2

1.3.2 VEGF & VEGF-R

1.3.3 EGF-R

1.3.4 CD20

1.4 Other Cancer Antibodies

  1. Other Anti-Inflammatory Antibodies:

2.1 Dermatology

2.2 Rheumatoid & Autoimmune

2.3 Neuro-Inflammation (multiple sclerosis, myasthenia gravis)

2.4 Pulmonary & Respiratory

2.5 Gastrointestinal

  1. Anti-TNF Antibodies
  2. Cardiometabolic Antibodies
  3. Ophthalmic Antibodies
  4. Insulin and Insulin Analogs
  5. Recombinant Coagulation Factors
  6. Established Therapeutic Proteins:

8.1 Interferon beta (IFN-β)

8.2 Erythropoiesis Stimulating Agent (ESA)

8.3 human Growth Hormone (hGH)

8.4 Granulocyte Colony Stimulating Factor (G-CSF)

8.5 Follicle Stimulating Hormone (FSH)

  1. Anti-Infective Antibodies
  2. Enzyme Replacement Therapy (ERT)
  3. Migraine & Neurodegenerative Disease Antibodies
  4. Other Proteins:

12.1 Cardiometabolic Proteins

12.2 Cancer Proteins

12.3 Various Proteins

  1. Selected Biosimilar Antibodies & Proteins
  2. Selected Other Biologics

14.1 DNA

14.2 Cell Therapy

14.3 RNA

The report 2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics can be acquired at La Merie Publishing’s online store www.lamerie.com: https://lamerie.com/report/2022-sales-of-recombinant-therapeutic-antibodies-proteins-biosimilars-other-biologics-copy/

About La Merie Publishing

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. La Merie Publishing prepares brief and full reports. La Merie Publishing products can be purchased in the online store www.lamerie.com and from selected Resellers.

La Merie Publishing offers the service of custom report preparation for corporate clients, including, but not limited to, pipeline analysis reports, drug profiles and any other competitive intelligence elaboration of interest.

SOURCE: La Merie Publishing